PHVS (Pharvaris N.V. Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by PHVS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-11 | Robert Glassman | Director | MIXED | — | — |
| 2026-09-09 | Peng Lu | President | MIXED | — | — |
| 2026-08-18 | Berndt Modig | Chief Executive Officer | Sell | — | — |
| 2026-08-13 | Peng Lu | President | F | — | — |
| 2026-07-15 | Berndt Modig | Chief Executive Officer | Sell | — | — |
| 2026-07-14 | Peng Lu | Chief Medical Officer | F | — | — |
| 2026-07-01 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sell | — | — |
| 2026-07-01 | Anne Lesage | Chief Early Development | MIXED | — | — |
| 2026-06-29 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sell | — | — |
| 2026-06-29 | Anne Lesage | Chief Early Development | MIXED | — | — |
| 2026-06-29 | Peng Lu | Chief Medical Officer | MIXED | — | — |
| 2026-06-23 | Peng Lu | Chief Medical Officer | MIXED | — | — |
| 2026-06-17 | Berndt Modig | Chief Executive Officer | Sell | — | — |
| 2026-06-16 | Peng Lu | Chief Medical Officer | F | — | — |
| 2026-06-15 | Peng Lu | Chief Medical Officer | F | — | — |
| 2026-06-08 | Anna Nijdam | Principal Accounting Officer | Sell | — | — |
| 2026-05-26 | David W. Nassif | CFO / CLO | Sell | — | — |
| 2026-05-26 | Viviane Monges | Director | Sell | — | — |
| 2026-05-26 | Anna Nijdam | Principal Accounting Officer | MIXED | — | — |
| 2026-05-22 | Elisabeth Bjork | Director | MIXED | — | — |
| 2026-05-22 | Berndt Modig | Chief Executive Officer | — | — | — |
| 2026-05-20 | Berndt Modig | Chief Executive Officer | Sell | — | — |
| 2026-05-19 | Wim Souverijns | Chief Commercial Officer | Sell | — | — |
| 2026-05-19 | Stefan Andreas Abele | Chief Technical Ops Officer | Sell | — | — |
| 2026-05-19 | Robert Glassman | Director | MIXED | — | — |
| 2026-05-13 | Peng Lu | Chief Medical Officer | F | — | — |
| 2026-05-05 | Peng Lu | Chief Medical Officer | MIXED | — | — |
| 2026-05-01 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sell | — | — |
| 2026-05-01 | Anne Lesage | Chief Early Development | MIXED | — | — |
| 2026-05-01 | Peng Lu | Chief Medical Officer | MIXED | — | — |
| 2026-04-24 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sell | — | — |
| 2026-04-24 | Peng Lu | Chief Medical Officer | MIXED | — | — |
| 2026-04-24 | Anne Lesage | Chief Early Development | MIXED | — | — |
| 2026-04-20 | Peng Lu | Chief Medical Officer | F | — | — |
| 2026-04-20 | Berndt Modig | Chief Executive Officer | Sell | — | — |
| 2026-04-14 | Anna Nijdam | Principal Accounting Officer | F | — | — |
| 2026-04-10 | Berndt Modig | Chief Executive Officer | Sell | — | — |
| 2026-04-08 | Anna Nijdam | Principal Accounting Officer | F | — | — |
| 2026-04-03 | Anna Nijdam | Principal Accounting Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 1,080,625 | — |
| — | Director | 315,167 | — |
| — | Chief Early Development | 152,719 | — |
| — | CFO / CLO | 120,300 | — |
| — | President | 80,179 | — |
| — | Principal Accounting Officer | 46,275 | — |
| — | Chief Commercial Officer | 45,111 | — |
| — | Chief Technical Ops Officer | 35,194 | — |
| — | Director | 15,167 | — |
| — | Director | 15,167 | — |
| — | Director | 5,500 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PHVS quote page; the site-wide leaderboard is on the insider transactions hub.